GlassScriptPrepare for your visit
Catherine Tucker
Surgical Oncology · Medford, MA · NPI 1730130832
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$850.28
in general payments reported to CMS, 2019-2025 · $118 in 2025
The $118 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Who reported paying
General payments only, top 6 by amount.
- Focal Therapeutics, INC. $367.85
- Dilon Technologies, INC. $167.25
- Myriad Genetic Laboratories, INC. $151.42
- Merit Medical Systems INC $73.31
- Allergan, INC. $66.62
- Astellas Pharma US INC $23.83
Drugs and devices associated with these payments
Hemoblast Bellows Myrisk Savi Scout Veozah
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Catherine Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1209789/catherine-tucker